Author

C. Martinelli

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · EClinicalMedicine · 0 citations

Case report Open access Sep 2026

[Efficacy and safety of sacituzumab govitecan in patients with metastatic HR+/HER2- pleomorphic lobular breast cancer complicated by renal impairment.]

The case concerns a 68-year-old female patient with metastatic HR-positive/HER2-negative pleomorphic lobular breast carcinoma and severe chronic renal impairment since diagnosis, previously treated with multiple lines of therapy. At diagnosis in September 2021, the disease was already metastatic, with bone, nodal, and...

C. Martinelli · Recenti progressi in medicin... · 0 citations

Review Open access Jul 2026

Unraveling the use of vaccine therapy in HER-2 positive breast cancer: a comprehensive review of current state and future perspectives

While advanced-stage BC often presents an immunosuppressive tumor microenvironment that hinders vaccine efficacy, early-stage disease offers a more favorable immunological milieu for inducing robust and durable T-cell responses.

A. Caltavituro, C. Martinelli, M. Palleschi et al. · Journal of Experimental &amp... · 0 citations